Nateglinide

Nateglinide
Clinical data
Trade names Starlix
AHFS/Drugs.com Monograph
MedlinePlus a699057
License data
Routes of
administration
Oral
ATC code A10BX03 (WHO)
Legal status
Legal status
Pharmacokinetic data
Protein binding 98%
Biological half-life 1.5 hours
Identifiers
CAS Number 105816-04-4 YesY
PubChem (CID) 60026
IUPHAR/BPS 6833
DrugBank DB00731 YesY
ChemSpider 10482084 YesY
UNII 41X3PWK4O2 YesY
KEGG D01111 N
ChEBI CHEBI:31897 N
ChEMBL CHEMBL286559 N
ECHA InfoCard 100.170.086
Chemical and physical data
Formula C19H27NO3
Molar mass 317.423 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Pharmacology

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Contraindications

Nateglinide is contraindicated in patients who:

Comparisons with other drugs for type 2 diabetes

A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."

Dosage

Nateglinide is delivered in 60 mg & 120 mg tablet form.

See also

References

  1. Rosenstock, Julio Rosenstock; Hassman, David R.; Madder, Robert D.; Brazinsky, Shari A.; Farrell, James; Khutoryansky, Naum; Hale, Paula M. (June 2004), "Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study", Diabetes Care, American Diabetes Association, 27 (6): 1265–1270, doi:10.2337/diacare.27.6.1265, retrieved 2014-11-20
This article is issued from Wikipedia - version of the 9/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.